Cord blood stem cell application is increasing a faster rate than other stem cell techniques because of its efficient and cost effective treatment process. Cord blood is assisting the healthcare industry to discover novel therapies for chronic diseases. UCB stem cell market is evidenced significant growth due to increasing public awareness and government support.
Umbilical cord blood stem cells are potential stem cells that can convert into any type of -determined cells. Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include – Adult stem cell and embryonic stem cells. Government authorities are supporting the research and clinical trials of cord blood stem cell, which is currently increasing the interest of healthcare companies to invest in research and commercialization of cord blood stem cell therapies. Athersys, California Stem Cell Inc., and Cytori Therapeutics Inc. are engaged in the development of novel stem cell therapies from cord blood. Ethical issues regarding cord blood sample application is creating biasness among donor, which is majorly influencing the market.
Allied Market Research today announced the most comprehensive and strategically analyzed report titled World Stem Cell Umbilical Cord Blood (UCB) Market(Storage Services, Therapeutics, Applications and Geography) – Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012 – 2020″ The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020.The storage service market was valued at $7.4billion in 2013.
Get the PDF brochure of this market insight@ https://www.alliedmarketresearch.com/request-sample/114
ncrease in the prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. Has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.
Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries, however patents for UCB stem cells are comparatively less in developing economies.
Do Purchase Inquiry@ https://www.alliedmarketresearch.com/purchase-enquiry/114
According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Company profiles in this report include – Advanced Cell Technology Inc., California Stem Cell Inc., Cytori Therapeutics Inc., Mesoblast Limited, Opexa Therapeutics Inc.(USA), Athersys Inc., Geron Corporation, and Neostem Inc.